Table 1 The demographics and clinical characteristics of DLBCL and validation groups

Gender

 Female/male

28/36

24/15

Age (years)

51 (37–61)

51 (42–64)

Ann Arbor staging

 I

2

4

 II

28

10

 III

19

10

 IV

15

15

IPI

 0

10

5

 1

19

6

 2

14

15

 3

15

8

 4

4

4

 5

2

1

Lymphoma SUV_max

23.69 ± 6.94

22.14 ± 6.62

Lg(TMTV)

1.98 ± 0.57

1.94 ± 0.69

Lg(TLG)

3.10 ± 0.59

3.03 ± 0.70